Teva And Alvotech Strike US Biosimilars Pact
Deal Covers Five Biosimilar Candidates With $35bn Brand Value
Teva and Alvotech have announced a major biosimilars alliance covering five products for the US market.
You may also be interested in...
Alvogen sister company Alvotech is continuing to extend its network of commercial partners by expanding its partnership with DKSH, a Swiss market expansion services group, for the commercialization of six biosimilars in Asian markets.
Editas regains rights to ocular programs first partnered with Allergan in 2017. Newly public F-star will focus on bispecific antibodies for cancer, TriSalus acquires oncology candidate from Dynavax.
In a busy second quarter for Teva, a COVID-19 slump acted as a correction to the related boost in demand seen in the first quarter of 2020.